Multiple Myeloma — Variants & evidence

Loading cancer entity…

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E3
(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID463 In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type. PMID 23612012 · Andrulis et al., 2013 · Open in CIViC	civic
Vemurafenib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1698 A 65-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E… (full text at CIViC) PMID 24997557 · Sharman et al., 2014 · Open in CIViC	civic
〃	Predictive	C	Supports Sensitivity Response	2	accepted	EID1699 A 54-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and received an autologous stem cell transplant. Genomic profiling of the bone biopsy revealed BRAF V600… (full text at CIViC) PMID 24997557 · Sharman et al., 2014 · Open in CIViC	civic
CCND1 Overexpression1
Bortezomib	Predictive	C	Supports Sensitivity Response	3	submitted	EID7788 Bone marrow specimens from 20/47 patients treated with bortezomib were analyzed. Researchers analyzed CCND1, CCND2, and CCND3 expression using real-time PCR. Results show all patients with CCND1 ove… (full text at CIViC) PMID 20578819 · Ngo et al., 2010 · Open in CIViC	civic
CRBN Mutation1
Lenalidomide + PomalidomideSubstitutes	Predictive	C	Supports Resistance	3	accepted	EID1766 A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were obs… (full text at CIViC) PMID 23480694 · Egan et al., 2013 · Open in CIViC	civic
CTAG1B Overexpression1
Letetresgene Autoleucel	Predictive	B	Supports Sensitivity Response	3	accepted	EID2940 Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing … (full text at CIViC) PMID 26193344 · Rapoport et al., 2015 · Open in CIViC	civic
CTAG2 Overexpression1
Letetresgene Autoleucel	Predictive	B	Supports Sensitivity Response	3	accepted	EID2941 Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing … (full text at CIViC) PMID 26193344 · Rapoport et al., 2015 · Open in CIViC	civic
FGFR3 F384L1
Midostaurin	Predictive	D	Supports Sensitivity Response	2	submitted	EID10410 Cell line LP1 expressing FGFR3 F384L was treated with small molecule inhibitor PKC412, with relative viability rising above 1.1/1.0 at both 50 nM and 100 nM. Relative viability dropped to 0.96/1.0 at … (full text at CIViC) PMID 16091734 · Chen et al., 2005 · Open in CIViC	civic
FGFR3 G802_X807del + FGFR3 Fusion1
Erdafitinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID11033 Analysis of a single patient is reported from a phase II trial (NCT02952573) testing erdafitinib in relapsed/refractory myeloma patients with or without FGFR3 mutations. The single patient (52 year ol… (full text at CIViC) PMID 36639200 · Croucher et al., 2023 · Open in CIViC	civic
FGFR3 K508M1
(oncogenic)	Oncogenic	D	Does Not Support Oncogenicity	2	submitted	EID11804 The study found that FGFR3 interacts with a regulatory subunit of PI3K, and this interaction negatively regulates the Ras/ERK/MAPK pathway in response to FGFR3 activity. This interaction could be a po… (full text at CIViC) PMID 19286672 · Salazar et al., 2009 · Open in CIViC	civic
FGFR3 K650E3
(oncogenic)	Oncogenic	D	Supports Oncogenicity	1	submitted	EID10383 Xenografts of multiple myeloma cell line OPM2 (FGFR3 K650E) into nude mice resulted in tumor growth. PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
Midostaurin	Predictive	D	Supports Sensitivity Response	3	submitted	EID10407 PKC412 inhibited the growth of FGFR3 K650E-transformed Ba/F3 cells. Researchers introduced an N540D mutation to FGFR3-transformed Ba/F3 cells, which reduces inhibition of the FGFR3 K650E-transformed c… (full text at CIViC) PMID 16091734 · Chen et al., 2005 · Open in CIViC	civic
R3Mab	Predictive	D	Supports Sensitivity Response	4	submitted	EID10365 In culture, monoclonal antibody R3Mab treatment inhibited the growth of multiple myeloma cell line UTMC-2 which has wild type FGFR3 but did not affect proliferation of multiple myeloma cell line KMS11… (full text at CIViC) PMID 19381019 ·
FGFR3 N540D1
Midostaurin	Predictive	D	Supports Resistance	3	submitted	EID10411 Ba/F3 cells transformed with FGFR3 K650E or TEL-FGFR3 had mutation FGFR3 N540D introduced to determine whether the FGFR3 mutants were the critical targets for PKC412-mediated cytotoxicity. The cells t… (full text at CIViC) PMID 16091734 · Chen et al., 2005 · Open in CIViC	civic
FGFR3 Overexpression3
Dovitinib	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID12294 Multiple myeloma (MM) is a neoplastic disorder of clonal B cells characterised by uncontrolled and aberrant proliferation of plasma cells within bone marrow, monoclonal protein in the blood or urine, … (full text at CIViC) PMID 25402977 · Scheid et al., 2015 · Open in CIViC	civic
R3Mab	Predictive	D	Supports Sensitivity Response	4	rejected	EID10363 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Predictive	D	Supports Sensitivity Response	4	submitted	EID10364 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro…
FGFR3 Y373C3
(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID10385 Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 Y375C both resulted in IL-3 independence with FGF1 dependence for growth. However, tumors grew when multiple myel… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
Midostaurin	Predictive	D	Supports Sensitivity Response	2	submitted	EID10408 t(4;14) positive multiple myeloma cell line OPM-1 and KMS11 expressing FGFR3 Y373C were inhibited by PKC412, with relative viability dropping to 0.9/1.0 at 100 nM, 0.8/1.0 to 200 nM, 0.58/1.0 at 400 … (full text at CIViC) PMID 16091734 · Chen et al., 2005 · Open in CIViC	civic
R3Mab	Predictive	D	Supports Sensitivity Response	4	submitted	EID10366 In culture, monoclonal antibody R3Mab treatment inhibited the growth of multiple myeloma cell line UTMC-2 which has wild type FGFR3 but did not affect proliferation of multiple myeloma cell line KMS11…
KRAS G122
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID487 In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC	civic
〃	Prognostic	B	Supports Poor Outcome	3	accepted	EID377 The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival. PMID 18528420 · Chng et al., 2008 · Open in CIViC	civic
KRAS G12A6
Melphalan	Predictive	B	Supports Resistance	2	accepted	EID2009 In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015). PMID 19284554 · Greco et al., 2009 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2010 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC) PMID 11524732 · Bezieau et al., 2001 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2011 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu…
KRAS G12C6
Melphalan	Predictive	B	Supports Resistance	2	rejected	EID2258 In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015). PMID 19284554 · Greco et al., 2009 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2259 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC) PMID 11524732 · Bezieau et al., 2001 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2260 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu…
KRAS G12D6
Melphalan	Predictive	B	Supports Resistance	2	rejected	EID2247 In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015). PMID 19284554 · Greco et al., 2009 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2248 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC) PMID 11524732 · Bezieau et al., 2001 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2249 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu…
KRAS G12S6
Melphalan	Predictive	B	Supports Resistance	2	rejected	EID2274 In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015). PMID 19284554 · Greco et al., 2009 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2275 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC) PMID 11524732 · Bezieau et al., 2001 · Open in CIViC	civic
〃	Predictive	B	Supports Resistance	—	submitted	EID2276 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu…
KRAS G131
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID488 In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC	civic
KRAS Q611
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID489 In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those wi… (full text at CIViC) PMID 18528420 · Chng et al., 2008 · Open in CIViC	civic
MCL1 Amplification1
Mcl-1 Inhibitor MIK665	Predictive	D	Supports Sensitivity Response	3	submitted	EID11768 In this preclinical study, the sensitivity of Multiple Myeloma tumors harboring 1q21 amplification to MCL-1 inhibitor S63845 was tested. The effect of the MCL-1 inhibitor was tested in 21 human myelom… (full text at CIViC) PMID 31856269 · Slomp et al., 2019 · Open in CIViC	civic
MYCL EXPRESSION1
I-BET151 + JQ1Substitutes	Predictive	D	Supports Sensitivity Response	1	accepted	EID1706 Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strong… (full text at CIViC) PMID 27276402 · Suzuki et al., 2016 · Open in CIViC	civic

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

BRAF V600E3

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID463

In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.

PMID 23612012 · Andrulis et al., 2013 · Open in CIViC

civic

Vemurafenib

Predictive

Supports Sensitivity Response

accepted

EID1698

A 65-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E… (full text at CIViC)

PMID 24997557 · Sharman et al., 2014 · Open in CIViC

civic

〃

Predictive

Supports Sensitivity Response

accepted

EID1699

A 54-year-old man presented with stage II myeloma. He was initially treated with chemotherapy and received an autologous stem cell transplant. Genomic profiling of the bone biopsy revealed BRAF V600… (full text at CIViC)

PMID 24997557 · Sharman et al., 2014 · Open in CIViC

civic

CCND1 Overexpression1

Bortezomib

Predictive

Supports Sensitivity Response

submitted

EID7788

Bone marrow specimens from 20/47 patients treated with bortezomib were analyzed. Researchers analyzed CCND1, CCND2, and CCND3 expression using real-time PCR. Results show all patients with CCND1 ove… (full text at CIViC)

PMID 20578819 · Ngo et al., 2010 · Open in CIViC

civic

CRBN Mutation1

Lenalidomide + PomalidomideSubstitutes

Predictive

Supports Resistance

accepted

EID1766

A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were obs… (full text at CIViC)

PMID 23480694 · Egan et al., 2013 · Open in CIViC

civic

CTAG1B Overexpression1

Letetresgene Autoleucel

Predictive

Supports Sensitivity Response

accepted

EID2940

Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing … (full text at CIViC)

PMID 26193344 · Rapoport et al., 2015 · Open in CIViC

civic

CTAG2 Overexpression1

Letetresgene Autoleucel

Predictive

Supports Sensitivity Response

accepted

EID2941

PMID 26193344 · Rapoport et al., 2015 · Open in CIViC

civic

FGFR3 F384L1

Midostaurin

Predictive

Supports Sensitivity Response

submitted

EID10410

Cell line LP1 expressing FGFR3 F384L was treated with small molecule inhibitor PKC412, with relative viability rising above 1.1/1.0 at both 50 nM and 100 nM. Relative viability dropped to 0.96/1.0 at … (full text at CIViC)

PMID 16091734 · Chen et al., 2005 · Open in CIViC

civic

FGFR3 G802_X807del + FGFR3 Fusion1

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID11033

Analysis of a single patient is reported from a phase II trial (NCT02952573) testing erdafitinib in relapsed/refractory myeloma patients with or without FGFR3 mutations. The single patient (52 year ol… (full text at CIViC)

PMID 36639200 · Croucher et al., 2023 · Open in CIViC

civic

FGFR3 K508M1

(oncogenic)

Oncogenic

Does Not Support Oncogenicity

submitted

EID11804

The study found that FGFR3 interacts with a regulatory subunit of PI3K, and this interaction negatively regulates the Ras/ERK/MAPK pathway in response to FGFR3 activity. This interaction could be a po… (full text at CIViC)

PMID 19286672 · Salazar et al., 2009 · Open in CIViC

civic

FGFR3 K650E3

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID10383

Xenografts of multiple myeloma cell line OPM2 (FGFR3 K650E) into nude mice resulted in tumor growth.

PMID 19381019 · Qing et al., 2009 · Open in CIViC

civic

Midostaurin

Predictive

Supports Sensitivity Response

submitted

EID10407

PKC412 inhibited the growth of FGFR3 K650E-transformed Ba/F3 cells. Researchers introduced an N540D mutation to FGFR3-transformed Ba/F3 cells, which reduces inhibition of the FGFR3 K650E-transformed c… (full text at CIViC)

PMID 16091734 · Chen et al., 2005 · Open in CIViC

civic

R3Mab

Predictive

Supports Sensitivity Response

submitted

EID10365

In culture, monoclonal antibody R3Mab treatment inhibited the growth of multiple myeloma cell line UTMC-2 which has wild type FGFR3 but did not affect proliferation of multiple myeloma cell line KMS11… (full text at CIViC)

PMID 19381019 ·

FGFR3 N540D1

Midostaurin

Predictive

Supports Resistance

submitted

EID10411

Ba/F3 cells transformed with FGFR3 K650E or TEL-FGFR3 had mutation FGFR3 N540D introduced to determine whether the FGFR3 mutants were the critical targets for PKC412-mediated cytotoxicity. The cells t… (full text at CIViC)

PMID 16091734 · Chen et al., 2005 · Open in CIViC

civic

FGFR3 Overexpression3

Dovitinib

Predictive

Does Not Support Sensitivity Response

submitted

EID12294

Multiple myeloma (MM) is a neoplastic disorder of clonal B cells characterised by uncontrolled and aberrant proliferation of plasma cells within bone marrow, monoclonal protein in the blood or urine, … (full text at CIViC)

PMID 25402977 · Scheid et al., 2015 · Open in CIViC

civic

R3Mab

Predictive

Supports Sensitivity Response

rejected

EID10363

Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro… (full text at CIViC)

PMID 19381019 · Qing et al., 2009 · Open in CIViC

civic

〃

Predictive

Supports Sensitivity Response

submitted

EID10364

FGFR3 Y373C3

(oncogenic)

Oncogenic

Supports Oncogenicity

submitted

EID10385

Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 Y375C both resulted in IL-3 independence with FGF1 dependence for growth. However, tumors grew when multiple myel… (full text at CIViC)

PMID 19381019 · Qing et al., 2009 · Open in CIViC

civic

Midostaurin

Predictive

Supports Sensitivity Response

submitted

EID10408

t(4;14) positive multiple myeloma cell line OPM-1 and KMS11 expressing FGFR3 Y373C were inhibited by PKC412, with relative viability dropping to 0.9/1.0 at 100 nM, 0.8/1.0 to 200 nM, 0.58/1.0 at 400 … (full text at CIViC)

PMID 16091734 · Chen et al., 2005 · Open in CIViC

civic

R3Mab

Predictive

Supports Sensitivity Response

submitted

EID10366

KRAS G122

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID487

In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (me… (full text at CIViC)

PMID 18528420 · Chng et al., 2008 · Open in CIViC

civic

〃

Prognostic

Supports Poor Outcome

accepted

EID377

The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.

PMID 18528420 · Chng et al., 2008 · Open in CIViC

civic

KRAS G12A6

Melphalan

Predictive

Supports Resistance

accepted

EID2009

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2010

Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC)

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2011

KRAS G12C6

Melphalan

Predictive

Supports Resistance

rejected

EID2258

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2259

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2260

KRAS G12D6

Melphalan

Predictive

Supports Resistance

rejected

EID2247

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2248

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2249

KRAS G12S6

Melphalan

Predictive

Supports Resistance

rejected

EID2274

In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015).

PMID 19284554 · Greco et al., 2009 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2275

PMID 11524732 · Bezieau et al., 2001 · Open in CIViC

civic

〃

Predictive

Supports Resistance

—

submitted

EID2276

KRAS G131

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID488

PMID 18528420 · Chng et al., 2008 · Open in CIViC

civic

KRAS Q611

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID489

In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those wi… (full text at CIViC)

PMID 18528420 · Chng et al., 2008 · Open in CIViC

civic

MCL1 Amplification1

Mcl-1 Inhibitor MIK665

Predictive

Supports Sensitivity Response

submitted

EID11768

In this preclinical study, the sensitivity of Multiple Myeloma tumors harboring 1q21 amplification to MCL-1 inhibitor S63845 was tested. The effect of the MCL-1 inhibitor was tested in 21 human myelom… (full text at CIViC)

PMID 31856269 · Slomp et al., 2019 · Open in CIViC

civic

MYCL EXPRESSION1

I-BET151 + JQ1Substitutes

Predictive

Supports Sensitivity Response

accepted

EID1706

Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strong… (full text at CIViC)

PMID 27276402 · Suzuki et al., 2016 · Open in CIViC

civic

Curated clinical evidence by variant and therapy